A pharmacogeneticist's look at drug effects and the drug development process: An overview

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 8, 2005, Pages 1299-1303

  Kalow, Werner ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Common diseases; Drug development; Drug metabolism; Drug targets; Drugs; Genes; Human races; Personalised medicine; Pharmacogenetics

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CLOZAPINE; CODEINE; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ISONIAZID; METOPROLOL; MIANSERIN; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PERPHENAZINE; PHENYTOIN; PROPRANOLOL; RISPERIDONE; SEROTONIN RECEPTOR; THIORIDAZINE; TIMOLOL; TOLBUTAMIDE; UNINDEXED DRUG; VENLAFAXINE; WARFARIN; ZUCLOPENTHIXOL;

DRUG APPROVAL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; DRUG UTILIZATION; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; RACE DIFFERENCE; REVIEW; TOXIC HEPATITIS;

CYTOCHROME P-450 CYP2D6; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHYSICIAN'S ROLE; TECHNOLOGY, PHARMACEUTICAL;

EID: 22744448610     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.8.1299     Document Type: Review

References (34)

1. KALOW W, MEYER UA, TYNDALE RF: Pharmacogenomics. Marcel Dekker, Inc., New York, Basel (2001).
2. LICINIO J, WONG ML: Pharmacogenomics. The Search for Individualized Therapies. Wiley-VCA, Weinheim, Germany (2002).
3. GRANT DM: Pharmacogenomics and the changing face of clinical pharmacology. Can. J. Clin. Pharmacol. (1999) 6:131-132.
4. EVANS DA, WHITE TA: Human acetylation polymorphism. J. Lab. Clin. Med. (1964) 63:394-403.
5. KANAZAWA H, OKADA A, MATSUSHIMA Y et al.: Determination of omeprazol and its metabolites in human plasma by liquid-chromatography-mass spectrometry. J. Cromatogr. A. (2002) 949:1-9.
6. KIRCHHEINER J, BROCKMOLLER J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. (2005) 77:1-16.
7. MAHE M, LOETSCHER E, FEUERBACK D, MULLER W, SEILER MP, SCHOEFTER P: Differential inverse agonist efficacies of SB-258759, SB-258741 and SB-269970 at human recombinant 5-HT7 receptors. Eur. J. Pharmacol. (2004) 495:97-102.
8. HJERDE E, DAHL SG, SYLTE I: Atypical and typical interactions with the dopamine receptor. Eur. J. Med. Chem. (2005) 40:185-194.
9. ROTH BL, HANIZAVAREH SM, BLUM AE: Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (2004) 174:17-24.
10. SCHOEDEL KA, HOFFMANN EB, RAO Y, SELLERS EM, TYNDALE RF: Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics (2004) 14:615-626.
11. WHITFIELD JB: Alcoholdehydrogenase and alcohol dependence: Variation in genotype-associated risk between populations. Am. J. Hum. Genet. (2002) 71:1247-1257.
12. SELLERS EM, TYNDALE RF, FERNANDES LC: Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug. Disc. Today (2003) 8:487-493.
13. RHODES JS, CRABBE JC: Gene expression induced by drugs of abuse. Curr. Opin. Pharmacol. (2005) 5:26-33.
14. INNOCENTI F, IYER L, RATAIN MJ: Pharmacogenetics of chemotherapeutic agents in cancer treatment. In: Pharmacogenomics: the search for indvidualized therapies. Licinio J, Wong ML (Eds), Wiley-VCH, Weinheim, Germany. (2002):283-310.
15. WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurinemethylytansferase activity. Am. J. Hum. Gen. (1980) 32:651-652.
16. SANDERSON J, ANSARI A, MARINAKI T, DULEY J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. (2004) 41:294-302.
17. ZANGER UM, RAIMUNDO S, EICHELBAUM M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. (2003) 369:23-37.
18. INGELMAN-SUNDBERG M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5:6-13.
19. TWYMAN RM: SNP discovery and typing technologies for pharmacogenomics. Curr. Top. Med. Chem. (2004) 4:1423-1431.
20. KALOW W: Historical aspects of pharmacogenetics. In: Pharmacogenetics. Kalow W, Meyer UA, Tyndale RF (Eds), Marcel Dekker, Inc., New York, Basel (2001):1-9.
21. WEIDENHAMMER EM, KAHL BF, WANG LM et al.: Multiplexed targeted gene expression profiling and genetic analysis on electronic microarrays. Clin. Chem. (2002) 48:1873-1882.
22. MADDEN SL, WANG C, LANDES G: Serial analysis of gene expression: Transcriptional insights into functional biology. In: Pharmacogenomics. Kalow W, Meyer UA, Tyndale RF (Eds), Marcel Dekker, Inc., New York, Basel (2001):223-252.
23. KALOW W: Interethnic differences in drug response. In: Pharmacogenomics. Kalow W, Meyer UA, Tyndale RF (Eds) Marcel Dekker, Inc., New York, Basel (2001):109-134.
24. ROSES AD: Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat. Rev. Genetics (2004) 5:645-656.
25. ARLEDGE T, FREEMAN A, ARBUCKLE J, MOSTELLER M, MANASCO P: Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience. Drug Metab. Rev. (2002) 32:387-395.
26. BUTCHER SP: Target discovery and validation in the postgenomic area. Neurochem. Res. (2003) 28:367-371.
27. NABHOLZ CE, OVERBECK J: Gene environment interactions and the complexity of human genetic diseases. J. Insur. Med. (2004) 36:47-53.
28. SCRIVER CR, BEAUDET AL, SLY WS, VALLE D: The metabolic and molecular bases of inherited disease (8th edn.) McGraw Hill, New York (2001).
29. KING RA, ROTTER JI, MOTULSKY AG: The genetic basis of common diseases (2nd edn.) Oxford University Press, New York (2002).
30. SCHADT EE, MONKS SA, FRIEND SH: A new paradigm for drug discovery: Integrating clinical, genetic, genomic, and molecular phenotype data to identify drug targets. Biochem. Soc. Trans. (2003) 31:437-443.
31. WALKER DJ: The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br. J. Clin. Pharmacol. (2004) 58:601-608.
32. DECOUSUS H, PERPOINT B, MISMETTI P, OLLAGNIER M, QUENEAU P: Good clinical practices in phase I studies. Fundam. Clin. Pharmacol. (1990) 4 (Suppl. 2):163S-165S.
33. ROSES AD: Pharmacogenetics and future drug development and delivery. Lancet (2000) 355:1358-1361.
34. FIJAL BA, HALL JM, WITTE JS: Clinical trials in the genomic area: Effects of protective genotypes on sample size and duration of trial. Control Clin. Trials (2000) 21:7-20.